Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

908 Devices (MASS) Long-Term Debt Repayments (2021 - 2023)

908 Devices (MASS) reported Long-Term Debt Repayments of $15.0 million for Q1 2023, little changed on a QoQ basis from $15.0 million in Q4 2022.

908 Devices (MASS) has 3 years of Long-Term Debt Repayments data on file, last reported at $15.0 million in Q1 2023.

  • Quarterly Long-Term Debt Repayments changed N/A year-over-year to $15.0 million in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $15.0 million (down 49.15% YoY) and the FY2023 annual result came in at $15.0 million, down 75.0% from the prior year.
  • Long-Term Debt Repayments held at $15.0 million in Q1 2023 per MASS's latest filing, from $15.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $15.0 million in Q4 2022 and bottomed at $500000.0 in Q1 2021.
  • The 3-year median for Long-Term Debt Repayments is $14.8 million (2021), against an average of $11.2 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 908 Devices 314.43 Mn 202.69 Mn 6.88 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2023 15.00 Mn
Mar 31, 2023 15.00 Mn
Dec 31, 2022 15.00 Mn
Dec 31, 2022 15.00 Mn
Jun 30, 2021 14.50 Mn
Jun 30, 2021 14.50 Mn
Mar 31, 2021 500,000.00
Mar 31, 2021 500,000.00